Cellular Biomedicine Group of Shanghai and the Bay Area has begun a China Phase I clinical trial of its newly optimized CAR-T immunotherapy. C-CAR011 is a construct of the CD19 CAR-T therapy that CBMG in-licensed from Beijing’s PLA General Hospital (the 301) last year. It will be tested as a treatment for patients with refractory Diffuse Large B-cell Lymphoma. CBMG is developing immunotherapies for cancer and stem cell treatments for degenerative diseases.
